Champions Oncology (CSBR) Return on Capital Employed (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Return on Capital Employed of 14.62% for Q2 2026, down 7428.0% year-over-year from 0.2% in Q2 2025, and up 51.94% quarter-over-quarter from 30.43% in Q1 2026.
Champions Oncology (CSBR) Return on Capital Employed (2011 - 2026) Analysis & Trends
Champions Oncology's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 14.62% for Q2 2026.
- In Q2 2026, Return on Capital Employed fell 7428.0% year-over-year to 14.62%; the TTM figure through Apr 2026 stood at 14.62% (down 7428.0% YoY), while the FY2026 annual figure was 11.7%, down 9625.0% from the prior year.
- Return on Capital Employed for Q2 2026 stood at 14.62%, up from 30.43% in the prior quarter.
- The five-year high for Return on Capital Employed was 77.99% in Q1 2025, with the low at 172.4% in Q1 2024.
- The 5-year median for Return on Capital Employed is 13.63% (2024), against an average of 26.07%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed plunged 15269 bps in 2024, then jumped 25039 bps in 2025.
- Champions Oncology's Return on Capital Employed stood at 1.45% in 2022, then slumped by 8104 bps to 116.39% in 2023, then soared by 89 bps to 12.64% in 2024, then surged by 307 bps to 26.18% in 2025, then sank by 156 bps to 14.62% in 2026.
- Business Quant data shows CSBR's Return on Capital Employed at 14.62% in Q2 2026, 30.43% in Q1 2026, and 26.18% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | -14.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -14.62% |
| Jan 31, 2026 | -30.43% |
| Oct 31, 2025 | 26.18% |
| Jul 31, 2025 | 30.83% |
| Apr 30, 2025 | 59.65% |
| Jan 31, 2025 | 77.99% |
| Oct 31, 2024 | -12.64% |
| Jul 31, 2024 | -54.55% |
| Apr 30, 2024 | -149.54% |
| Jan 31, 2024 | -172.40% |
| Oct 31, 2023 | -116.39% |
| Jul 31, 2023 | -64.16% |
| Apr 30, 2023 | -38.94% |
| Jan 31, 2023 | -19.70% |
| Oct 31, 2022 | 1.45% |
| Jul 31, 2022 | 2.73% |
| Apr 30, 2022 | 3.57% |
| Jan 31, 2022 | 1.69% |
| Oct 31, 2021 | 2.60% |
| Jul 31, 2021 | 1.03% |